Oxaloacetate in Myasthenia Gravis

Status Not yet recruiting

Clinical Trial Summary

This is a phase 1 clinical trial studying whether or not oxaloacetate has a positive effect on patients with Myasthenia Gravis. Patients will be assigned to one of three cohorts which will determine the dose of oxaloacetate they will be given. Subjects will take the study drug for 4 weeks and be on placebo for 4 weeks.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04965987
Study type	Interventional
Source	University of Kansas Medical Center
Contact	Andrew J Heim
Phone	9139459926
Email	aheim2@kumc.edu
Status	Not yet recruiting
Phase	Phase 1
Start date	October 2021
Completion date	April 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05039190` - Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients	Phase 3
Recruiting	`NCT04561557` - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System	Early Phase 1
Completed	`NCT01727193` - The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy	Phase 3
Completed	`NCT00285350` - Mycophenolate Mofetil in Myasthenia Gravis	Phase 3
Recruiting	`NCT05890833` - The Risk of Falls Index for Patients With Neuromuscular Disorders
Completed	`NCT05694234` - Influences of Sugammadex on Postoperative Progress in Patients With Myasthenia Gravis Undergoing Video-assisted Thoracoscopic Thymectomy: Retrospective Study
Recruiting	`NCT05635266` - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Not yet recruiting	`NCT05095103` - Immune Profiles in Myasthenia Gravis
Completed	`NCT02774239` - A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG)	Phase 3
Terminated	`NCT02102594` - Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)	Phase 2
Completed	`NCT02066519` - Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis	N/A
Completed	`NCT02118805` - Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
Terminated	`NCT01828294` - Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis	Phase 1
Terminated	`NCT00727194` - Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis	Phase 2
Completed	`NCT04590716` - Help Build an A.I. Model to Predict Myasthenia Gravis Symptom Patterns and Flares
Recruiting	`NCT04837625` - Study of Myasthenic Crisis in China
Not yet recruiting	`NCT01469858` - Perception and Multisensory Integration in Neurological Patients Using fMRI	N/A
Completed	`NCT05408702` - Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes
Completed	`NCT03205306` - Myasthenia Gravis and Psyche
Recruiting	`NCT06106672` - Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis	Phase 1/Phase 2